The correct course of action is to charge the manufacturers of addictive drugs for the recovery costs.
It would discourage pushing over prescription, encourage more work into accurately identifying addictiveness (and presumably reducing it), and if all else fails would encourage them to develop cheap drugs to recover from addiction.
It would discourage pushing over prescription, encourage more work into accurately identifying addictiveness (and presumably reducing it), and if all else fails would encourage them to develop cheap drugs to recover from addiction.